Immuron (IMRN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immuron Limited’s CEO, Steven Lydeamore, is set to present at the Sharewise conference on July 9, 2024, discussing the company’s sales growth for Travelan, their clinical program for Clostridioides difficile, and forthcoming milestones. Interested parties can attend the presentation through a live Zoom webinar, with a Q&A session to follow. Immuron, an Australian biopharmaceutical company, specializes in the development and commercialization of oral antibodies for infectious diseases, with products like Travelan offering protection against travelers’ diarrhea.
For further insights into IMRN stock, check out TipRanks’ Stock Analysis page.